Ziopharm Oncology (ZIOP) Misses Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Ziopharm Oncology (ZIOP) Misses Q1 EPS by 1c

Ziopharm Oncology Reports First Quarter 2020 Financial Results and Provides Corporate Update

May 7, 2020 4:06 PM EDT

Regulatory discussions with FDA advance Ziopharm TCR-T IND process Enrollment on track in Controlled IL-12 phase 2 clinical trial with Regenerons Libtayo®;Controlled IL-12 clinical data update at ASCO 2020 Work restrictions at NCI and MD Anderson impacting clinical trials;Ziopharm working to minimize delays Prioritizing Greater China CAR-T clinical trial given advancements Balance sheet strengthened in Q1; cash of $171 million to fund operations into mid-2022

Company to host conference call and webcast today, May 7, at 4:30 p.m. EDT

BOSTON, May 07, 2020... More